|
1
|
Hawkins BM, Stavrakis S, Rousan TA,
Abu-Fadel M and Schechter E: Coronary slow flow - prevalence and
clinical correlations. Circ J. 76:936–942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beltrame JF: Defining the coronary slow
flow phenomenon. Circ J. 76:818–820. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tambe AA, Demany MA, Zimmerman HA and
Mascarenhas E: Angina pectoris and slow flow velocity of dye in
coronary arteries - a new angiographic finding. Am Heart J.
84:66–71. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cutri N, Zeitz C, Kucia AM and Beltrame
JF: ST/T wave changes during acute coronary syndrome presentation
in patients with the coronary slow flow phenomenon. Int J Cardiol.
146:457–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Horjeti B and Goda A: Acute ischemia
manifestation in a patient with coronary slow flow phenomenon. J
Electrocardiol. 45:277–279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saya S, Hennebry TA, Lozano P, Lazzara R
and Schechter E: Coronary slow flow phenomenon and risk for sudden
cardiac death due to ventricular arrhythmias: A case report and
review of literature. Clin Cardiol. 31:352–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X and Nie SP: The coronary slow flow
phenomenon: Characteristics, mechanisms and implications.
Cardiovasc Diagn Ther. 1:37–43. 2011.PubMed/NCBI
|
|
8
|
Yoshida H, Shoda T, Yanai H, Ikewaki K,
Kurata H, Ito K, Furutani N, Tada N, Witztum JL and Tsimikas S:
Effects of pitavastatin and atorvastatin on lipoprotein oxidation
biomarkers in patients with dyslipidemia. Atherosclerosis.
226:161–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colhoun HM, Betteridge DJ, Durrington PN,
Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI,
Charlton-Menys V and Fuller JH; CARDS investigators, : Primary
prevention of cardiovascular disease with atorvastatin in type 2
diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):
Multicentre randomised placebo-controlled trial. Lancet.
364:685–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Caliskan M, Erdogan D, Gullu H, Topcu S,
Ciftci O, Yildirir A and Muderrisoglu H: Effects of atorvastatin on
coronary flow reserve in patients with slow coronary flow. Clin
Cardiol. 30:475–479. 2017. View Article : Google Scholar
|
|
11
|
Baykan AO, Kalkan GY, Sahin DY, Elbasan Z,
Gur M, Seker T, Turkoglu C and Caylı M: Coronary flow velocity
reserve in donor artery and myocardial performance index after
successful recanalization of chronic total coronary occlusions. J
Invasive Cardiol. 27:E75–E81. 2015.PubMed/NCBI
|
|
12
|
Gibson CM, Cannon CP, Daley WL, Dodge JT
Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T,
Poole WK, et al: TIMI frame count: A quantitative method of
assessing coronary artery flow. Circulation. 93:879–888. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nie SP, Wang X, Geng LL, Liu BQ, Li J,
Qiao Y, Liu XM, Luo TY, Dong JZ, Liu XH, et al: Anatomic properties
of coronary arteries are correlated to the corrected thrombolysis
in myocardial infarction frame count in the coronary slow flow
phenomenon. Coron Artery Dis. 23:174–180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sugiyama M, Ohashi M, Takase H, Sato K,
Ueda R and Dohi Y: Effects of atorvastatin on inflammation and
oxidative stress. Heart Vessels. 20:133–136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bielecka-Dabrowa A, Mikhailidis DP, Rizzo
M, von Haehling S, Rysz J and Banach M: The influence of
atorvastatin on parameters of inflammation left ventricular
function, hospitalizations and mortality in patients with dilated
cardiomyopathy − 5-year follow-up. Lipids Health Dis. 12:472013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kopetz V, Kennedy J, Heresztyn T, Stafford
I, Willoughby SR and Beltrame JF: Endothelial function, oxidative
stress and inflammatory studies in chronic coronary slow flow
phenomenon patients. Cardiology. 121:197–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon HJ, Jeong MH, Cho SH, Kim KH, Lee MG,
Park KH, Sim DS, Yoon NS, Hong YJ, Kim JH, et al: Endothelial
dysfunction and increased carotid intima-media thickness in the
patients with slow coronary flow. J Korean Med Sci. 27:614–618.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beltrame JF, Limaye SB, Wuttke RD and
Horowitz JD: Coronary hemodynamic and metabolic studies of the
coronary slow flow phenomenon. Am Heart J. 146:84–90. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Desjardins F and Balligand JL: Nitric
oxide-dependent endothelial function and cardiovascular disease.
Acta Clin Belg. 61:326–334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toda N, Tanabe S and Nakanishi S: Nitric
oxide-mediated coronary flow regulation in patients with coronary
artery disease: Recent advances. Int J Angiol. 20:121–134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Atar S, Ye Y, Lin Y, Freeberg SY, Nishi
SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR and Birnbaum Y:
Atorvastatin-induced cardioprotection is mediated by increasing
inducible nitric oxide synthase and consequent S-nitrosylation of
cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 290:H1960–H1968.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajamannan NM, Subramaniam M, Stock SR,
Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow
RO and Spelsberg TC: Atorvastatin inhibits calcification and
enhances nitric oxide synthase production in the
hypercholesterolaemic aortic valve. Heart. 91:806–810. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mason RP, Corbalan JJ, Jacob RF, Dawoud H
and Malinski T: Atorvastatin enhanced nitric oxide release and
reduced blood pressure, nitroxidative stress and rantes levels in
hypertensive rats with diabetes. J Physiol Pharmacol. 66:65–72.
2015.PubMed/NCBI
|
|
24
|
Wu YW, Kao HL, Huang CL, Chen MF, Lin LY,
Wang YC, Lin YH, Lin HJ, Tzen KY, Yen RF, et al: The effects of
3-month atorvastatin therapy on arterial inflammation,
calcification, abdominal adipose tissue and circulating biomarkers.
Eur J Nucl Med Mol Imaging. 39:399–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van de Ree MA, Huisman MV, Princen HMG,
Meinders AE and Kluft C; DALI-Study Group, : Strong decrease of
high sensitivity C-reactive protein with high-dose atorvastatin in
patients with type 2 diabetes mellitus. Atherosclerosis.
166:129–135. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang YY, Fan YC, Wang M, Wang D and Li
XH: Atorvastatin attenuates the production of IL-1β, IL-6, and
TNF-α in the hippocampus of an amyloid β1-42-induced rat model of
Alzheimer's disease. Clin Interv Aging. 8:103–110. 2013.PubMed/NCBI
|
|
27
|
Wang H, Cui XX, Goodin S, Ding N, Van
Doren J, Du Z, Huang MT, Liu Y, Cheng X, Dipaola RS, et al:
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a
combination of atorvastatin and celecoxib. Oncol Rep. 31:835–841.
2014.PubMed/NCBI
|
|
28
|
Chang CZ, Wu SC, Lin CL, Hwang SL, Howng
SL and Kwan AL: Atorvastatin preconditioning attenuates the
production of endothelin-1 and prevents experimental vasospasm in
rats. Acta Neurochir (Wien). 152:1399–1406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Minami Y, Satoh M, Maesawa C, Takahashi Y,
Tabuchi T, Itoh T and Nakamura M: Effect of atorvastatin on
microRNA 221/222 expression in endothelial progenitor cells
obtained from patients with coronary artery disease. Eur J Clin
Invest. 39:359–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oikonomou E, Tousoulis D, Siasos G,
Zaromitidou M, Chrysohoou C, Kokkou E, Tourikis P, Mazaris S,
Konsola T and Stefanadis C: The impact of high dose atorvastatin
treatment on endothelial progenitor cells, vascular function and
inflammatory status in ischemic heart failure. Eur Heart J. 34
Suppl 1:P5724. 2013. View Article : Google Scholar
|
